Yuki Saito: A pan-cancer landscape of driver alterations and their clinical actionability in Japanese patients
Yuki Saito, Postdoctoral researcher at Keisuke Kataoka Laboratory, shared a post by Keisuke Kataoka Laboratory on, X/Twitter adding:
“Happy to share our paper (my 1st paper as one of corresponding authors) out in Cancer Discovery! Using >48,000 Japanese clinical sequencing data in CCAT, we elucidated a pan-cancer landscape of driver alterations and their clinical actionability in Japanese patients.
Comparison with whites in AACR GENIE revealed higher TP53 mutation frequencies in Asians. Integration of CCAT, GENIE and TCGA revealed many co-occurring and exclusive relations between drivers, identifying co-occurrence of multiple mutations in epigenetic regulators.
More details in Keisuke Kataoka Laboratory threads. Kudos to amazing PhD student Sara Horie.”
Quoting Keisuke Kataoka Laboratory’s post:
“Excited to share our latest paper from Cancer Discovery. We used >48,000 samples from C-CAT, a real-world clinico-genomic database in Japan, to elucidate driver alterations and their clinical actionability in Japanese patients.”
Source: Yuki Saito/X and Keisuke Kataoka Laboratory/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023